Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Joseph Liechty

Vascular Surgery Plano, TX Medical Doctor

NPI 1043416316 CMS profile 1297543

4716 Alliance Blvd Ste 200, Plano, TX 75093

Open in the dashboard

General payments

$93,098

303 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Joseph Liechty of Plano, TX is reported in the CMS Open Payments database as having received $93,098 across 303 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Vascular Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,248 44
2024 General $24,505 76
2023 General $34,973 64
2022 General $16,739 67
2021 General $1,458 20
2020 General $362 12
2019 General $813 20

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Joseph Liechty
  • Vascular Surgery median
  • Middle half of Vascular Surgery
  • National median

In program year 2025, general payments to Joseph Liechty were reported at $14,248. Among 3,991 Vascular Surgery profiles paid that year, the median was $924 and the middle half received between $273 and $2,636.

Show as a table
Year Joseph Liechty Vascular Surgery median Middle half National median
2019 $813 $796 $226–$2,363 $163
2020 $362 $348 $118–$1,110 $114
2021 $1,458 $471 $158–$1,421 $132
2022 $16,739 $725 $222–$2,183 $149
2023 $34,973 $836 $257–$2,440 $160
2024 $24,505 $909 $252–$2,619 $164
2025 $14,248 $924 $273–$2,636 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Inari Medical, Inc. $64,553 130 payments
  2. Stryker Corporation $13,560 24 payments
  3. Medtronic, Inc. $10,892 49 payments
  4. Teleflex LLC $700 1 payment
  5. Endologix, Inc. $625 5 payments
  6. Boston Scientific Corporation $404 19 payments
  7. W. L. Gore & Associates, Inc. $311 6 payments
  8. Koya Medical, Inc. $247 1 payment
  9. Penumbra, Inc. $241 2 payments
  10. Terumo Medical Corporation $237 7 payments
  11. Other $1,327 59 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $46,950 22 payments
  2. Travel and Lodging $17,851 36 payments
  3. Consulting Fee $17,250 9 payments
  4. Food and Beverage $11,047 236 payments
Products named General payments · program years 2019–2025
  1. FLOWTRIEVER CATHETER, S $78,382 146 payments
  2. CT THROMBECTOMY SYSTEM KIT $76,612 140 payments
  3. IN.PACT Admiral $10,058 19 payments
  4. MANTA $700 1 payment
  5. Abre $401 10 payments
  6. Ovation $356 2 payments
  7. HawkOne $295 15 payments
  8. ENDOCROSS Device $269 3 payments
  9. Torus Stent Graft System $269 3 payments
  10. CLOTTRIEVER BOLD CATHETER $268 4 payments
  11. Other $4,627 135 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 4 drugs

Part D claims

120

Median for Vascular Surgery: 122

Drug cost

$50,180

Median for Vascular Surgery: $14,135

Branded share of claims

81.7%

Median for Vascular Surgery: 71%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Eliquis Apixaban Brand 59 $49,256
Cilostazol Generic 22 $441
Clopidogrel Clopidogrel Bisulfate Brand 18 $279
Hydrocodone-Acetaminophen Hydrocodone/Acetaminophen Brand 21 $205

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,087 Part D prescribers listed as Vascular Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 128 billing codes

Paid by Medicare

$180,273

Medicare's payments for the services billed

Medicare patients

365

Average age 74

Services billed

1,471

189 women, 176 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 55%
Arthritis 52%
Chronic kidney disease 46%
Diabetes 45%
Heart failure 33%
Atrial fibrillation 29%
Depression 29%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

303 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Vascular Surgery in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record